Clinical Outcomes of Hydrogel Spacer Injection Space OAR in Men Submitted to Hypofractionated Radiotherapy for Prostate Cancer

PIETRO PEPE1, MARIA TAMBURO2, MICHELE PENNISI1, DARIO MARLETTA2 and FRANCESCO MARLETTA2

1Urology Unit, Cannizzaro Hospital, Catania, Italy 2Radiotherapy Unit, Cannizzaro Hospital, Catania, Italy

Abstract. Background/Aim: To evaluate the clinical outcomes of men with prostate cancer (PCa) submitted to hydrogel spacer injection before hypofractionated radiotherapy (HRT).

Patients and Methods: From April 2018 to April 2020, 32 patients with clinically localized PCa underwent hydrogel injection Space OAR before HRT to the prostate and seminal vesicle; the prescription dose was 60 Gy in 20 fractions, 5 days/week over 4 weeks. PSA levels, genitourinary (GU) and gastrointestinal (GI) toxicities, and sexual function were prospectively evaluated.

Results: PSA levels at the median follow up of 15 months was 0.52 ng/ml; 28.1% vs. 78.1% patients had GI vs. GU Grade 0 acute toxicity and 93.7% vs. 0% had GI vs. GU Grade 0 late toxicity. Furthermore, 88.1% of patients kept pretreatment sexual potency. Conclusion: The use of the hydrogel Spacer OAR before HRT is useful for reducing acute and late GU and GI toxicities.

Prostate cancer (PCa) is the second most commonly diagnosed male malignancy (1) in the Western world; radical prostatectomy and external radiotherapy (RT) are currently recommended as definitive treatment alone or combination in men with organ confined, locally advanced and oligometastatic prostate cancer (PCa). In the last years, the advances in physics, engineering and imaging have been channeled into the development of image-guided intensity-modulated radiotherapy that has shown that increasing dose improves biochemical disease-free survival with acceptable acute and long-term toxicities (2, 3). In addition, recently, the use of a hydrogel spacer (Space OAR) between the rectum and the prostate has been approved to reduce rectal toxicity in prostate radiation therapy (4, 5).

In this study, the clinical outcomes of men submitted to hydrogel spacer injection followed by hypofractionated radiotherapy (HRT) were prospectively evaluated.

Patients and Methods

From April 2018 to April 2020, 32 patients (median age: 70 years; range=58-82 years) with clinically localized PCa were treated by HRT directed to the prostate and seminal vesicle. The median PSA was 7.7 ng/ml (range=4.1-23); 13 patients (40%) were at low risk (Grade Group 1), 16 (50%) at favorable intermediate risk (Grade Group 2) and only 3 (10%) at unfavorable intermediate risk (Grade Group 3) (6); moreover, all patients were without evidence of disease spread to the lymph nodes or the bones. The median prostate volume was 68.3 cm3 and the most frequent comorbidities are reported in Table I. PCa diagnosis was previously performed by transperineal extended prostate biopsy (median 20 cores) (7, 8) combined with targeted cores (4 cores) of multiparametric magnetic resonance imaging lesions (Prostate Imaging-Reporting and Data System score ≥3) suspicious for PCa (9, 10); 15/32 (46.8%) vs. 11/32 (34.4%) vs. 6/32 (18.8%) patients underwent initial vs. repeat vs. confirmatory biopsy (men enrolled in active surveillance protocol) (11).

All patients were selected for a hydrogel injection Space OAR before HRT; the injection of hydrogel was performed under sedation by transrectal ultrasound guidance. First, the dissection of the space between Denonvilliers’ fascia and the anterior rectum wall was performed with 5-15 ml of saline, then 10 ml of hydrogel were injected (Figure 1A) by a transperineal approach; furthermore, three gold fiducials were inserted transperineally at the prostate base and mid-gland (Figure 1B).

Patients were simulated 2 weeks after placement and abdominal computed tomography (CT) simulation was performed in the supine position with full bladder and empty rectum. These physiological conditions were maintained in all treatment fractions. CT simulation was obtained at 3 mm slice thickness using an immobilization device, extending from L1 to below the ischial tuberosities. CT simulation was preceded by MRI simulation in the treatment position. CT-MRI image registration was accomplished using the MIM-software (Maestro, version 7.0.5, MIM Software Inc., Cleveland, OH, USA).

This article is freely accessible online.

Correspondence to: Dr. Pietro Pepe, Urology Unit - Cannizzaro Hospital, Via Messina 829, Catania, Italy. Tel: +39 957263285, Fax: +39 957263259, e-mail: piepepe@hotmail.com

Key Words: Hydrogel spacer, Space OAR, intraprostastic fiducials, hypofractionated radiotherapy, prostate cancer.
The whole prostate and seminal vesicle were delineated as the clinical target volume (CTV). Non-uniform planning target volume (PTV) was defined by adding margins to CTV; the margin was 8 mm in the anterior, lateral, superior and inferior directions, while it was 4 mm in the posterior direction.

The rectum, urinary bladder, bowel, femoral heads and penile bulb were contoured as organs at risk. The rectum was delineated from the rectosigmoid flexure to the anus; the treatment planning system was Monaco-Elekta (Elekta AB, Stockholm, Sweden). The prescription dose was 60 Gy in 20 fractions 5 days/week over 4 weeks, the CTV was planned to receive at least 100% of the prescription dose and the PTV at least 95% with maximum dose at CTV <110% of the prescription dose.

Dose-volume constraints were: dose given to 30% of rectal volume <46 Gy, dose given to 50% of rectal volume <37 Gy, dose given to 30% urinary bladder volume <46 Gy, dose given to 30% urinary bladder volume <37 Gy, dose given to 5% left/right femoral head volume <43 Gy. Patients were treated with volumetric modulated arc therapy (VMAT) using the LINAC Synergy Elekta and pretreatment verification of the prostate was conducted using a kilovoltage cone-beam CT during each treatment session.

Patients were followed every 3 months for 2 years, and thereafter every 6 months. PSA relapse was determined according to the Phoenix consensus definition (nadir PSA value plus 2 ng/ml). Genitourinary (GU) and gastrointestinal (GI) toxicities were evaluated following RTOG/EORTC score. Acute toxicity was defined as that occurred within 3 months after the initiation of radiotherapy, while late toxicity was observed after 3 months. The sexual function was evaluated before and after RT by International Index of Erectile Function - 5 (IIEF-5) score evaluation.

Patients tolerated well the injection of Space OAR and completed the HRT treatment. PSA levels at the median follow up of 15 months was 0.52 ng/ml; in detail, the median PSA nadir was 0.355 ng/ml in 5 patients. Table II shows the acute and late GU and GI toxicities. Twenty-two (70%) men reported a normal sexual activity before HRT (median IIEF-5 score: 22; range=20-25); at a median follow up of 15 months from HRT, 18/22 (81.8%) men kept pretreatment sexual potency (median IIEF-5 score: 21; range=19-25).

**Discussion**

Standard radical radiotherapy has been traditionally performed by a fractionated schedule, using daily dose (40-45 fractions). The cell death following ionizing radiation is related to the linear-quadratic model that describes the relationship between cell survival, overall dose, and dose per fraction. The response of tissue to fraction size is described by alpha/beta ratio; the alpha/beta estimate for prostate cancer was 1.5, while most tumors are reported to have an alpha/beta of 10. Tissues with lower alpha/beta ratios demonstrated greater sensitivity to hypofractionation (12, 13). Standard external radiotherapy used for the treatment of PCs is associated with 5% or lower grade 3 toxicity rates, and grade 4 toxicity rates of less than 1%. The HRT refers to the delivery of 2.4-4.0 Gy per fraction daily over 4-6 weeks; it is well tolerated with the obvious economic and practical advantages associated with shorter treatment durations (14). There are three large randomized non-inferiority trials (15-17) evaluating the equivalence of hypofractionation with standard treatment; the CHHiP (14), RTOG 0415 (15) and PROFIT (16) studies included patients in different risk groups differing in the use of hormonal therapy; however, all studies showed similar results, demonstrating that the efficacy of hypofractionation is not inferior to standard treatment. They differed in the late toxicity outcomes; RTOG 0415 and CHHiP reported no difference in late toxicity, while PROFIT reported a lower rate of late toxicity in the hypofractionated arm.

Recently, a novel device, Space OAR, has been introduced in clinical practice with the intent to reduce toxicity in patients submitted to radiotherapy (18). The hydrogel is allocated between the prostate and the rectum to separate these two structures and to reduce the dose of radiation delivered to the rectum. The polyethylene glycol-based spacer, Space OAR hydrogel, implanted between the prostate gland and the rectum may significantly reduce the dose received by the rectum and the risk of rectal toxicity (19). Babar et al. (20) in a systematic review showed that Space OAR reduced the radiation dose volume to the rectum over numerous dosimetry levels; in detail, Space OAR significantly decreased acute Grade 1 diarrhea, late Grade 1 and Grade ≥2 rectal toxicities and urinary incontinence. Recently, Applewhite et al. (21) reported that hydrogel spacers can also be effectively used in patients previously submitted to prostate cryoablation who underwent salvage radiotherapy. In addition, the injection of Space OAR reduced significantly rectal dose sparing in men submitted to

<table>
<thead>
<tr>
<th>Table I. Clinical parameters and comorbidities of patients submitted to Space OAR injection before hypofractionated radiotherapy.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patients</td>
</tr>
<tr>
<td>-----------------------------------------------</td>
</tr>
<tr>
<td>Median age</td>
</tr>
<tr>
<td>Most frequent comorbidity</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>Initial PSA (ng/ml) median (range)</td>
</tr>
<tr>
<td>ISUP Grade Group 1 (3+3)</td>
</tr>
<tr>
<td>ISUP Grade Group 2 (3+4)</td>
</tr>
<tr>
<td>ISUP Grade Group 3 (4+3)</td>
</tr>
<tr>
<td>Prostate volume median cm³</td>
</tr>
</tbody>
</table>

ISUP: International Society of Urological Pathology.
brachytherapy (22, 23). On the other hand, rarely, major complications following Space OAR injection have been reported including, severe anaphylaxis, acute pulmonary embolism, prostatic or perineal abscess and sepsis, rectal wall erosion, and recto-urethral fistula (24).

In our series, the PSA value at median follow up of 15 months was 0.52 ng/ml; 9/32 (28.1%) vs. 25/32 (78.1%) had GI vs. GU Grade 0 acute toxicity and 30/32 (93.7%) vs. 0% men had GI vs. GU Grade 0 late toxicity. In detail, only 1 (3.1%) patient reported a GU late complication of Grade 3; moreover, 88.1% of patients (18/22) kept pretreatment sexual potency (median IIEF-5 score: 21).

Regarding our results, some considerations should be presented. First, the number of men submitted to Space OAR and fiducials injection is limited. Second, the follow up of the patients is short to evaluate long term oncological results especially in men with intermediate risk PCa. Third, there was no control group. Finally, the cost-effectiveness of hydrogel and fiducials injection should be compared with the reduction of hospital recovery and/or salvage treatment secondary to standard radiotherapy complications.

In conclusion, the use of the hydrogel Spacer OAR before HRT is well tolerated and reduces the incidence of acute and late GU and GI toxicities improving the quality of life of the patients.

Table II. Acute and late genitourinary (GU) and gastrointestinal (GI) toxicity score* in 32 men who underwent Space OAR injection before hypofractionated radiotherapy.

<table>
<thead>
<tr>
<th>Grade</th>
<th>GU (n=32)</th>
<th>GI (n=32)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Acute</td>
<td>Late</td>
</tr>
<tr>
<td>0</td>
<td>9</td>
<td>30</td>
</tr>
<tr>
<td>1</td>
<td>19</td>
<td>0</td>
</tr>
<tr>
<td>2</td>
<td>4</td>
<td>1</td>
</tr>
<tr>
<td>3</td>
<td>-</td>
<td>1</td>
</tr>
<tr>
<td>4</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

*Radiation Therapy Oncology Group (RTOG)/European Organisation for Research and Treatment of Cancer (EORTC).

Conflicts of Interest

The Authors declare no conflicts of interest regarding this study.

Authors’ Contributions

The Authors contributed equally in all aspects of this article.
References


Received June 20, 2021
Revised July 25, 2021
Accepted July 26, 2021